-

Cerus Corporation Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for the offering were $63.3 million, before deducting estimated offering expenses payable by Cerus.

BTIG, LLC acted as sole book-running manager for the offering.

A shelf registration statement on Form S-3 (File No. 333-219727) relating to the shares of common stock described above was previously filed by Cerus with the Securities and Exchange Commission ("SEC") and declared effective on January 8, 2018. You should read the prospectus in the registration statement and related final prospectus supplement that Cerus has filed with the SEC for complete information about Cerus and this offering. A final prospectus supplement and accompanying prospectus relating to the offering is available on the SEC's website located at http://www.sec.gov. Alternatively, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting BTIG, LLC at 65 East 55th Street, New York, NY, 10022, by email at equitycapitalmarkets@btig.com or by telephone at (212) 593-7555.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply. Based in Concord, California, Cerus develops and markets the INTERCEPT Blood System. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.

Contacts

Tim Lee – Investor Relations Director
Cerus Corporation
925-288-6137

Cerus Corporation

NASDAQ:CERS

Release Versions

Contacts

Tim Lee – Investor Relations Director
Cerus Corporation
925-288-6137

More News From Cerus Corporation

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world’s blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru...

Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company’s management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safe...

Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor...
Back to Newsroom